Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04882163
Title Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Celgene

B-cell lymphoma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma


Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab

Lenalidomide + Tafasitamab-cxix

Iberdomide + Polatuzumab vedotin-piiq + Rituximab

Iberdomide + Tafasitamab-cxix

Bendamustine + Polatuzumab vedotin-piiq + Rituximab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL | AUT

Additional content available in CKB BOOST